Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US

FDA Approval In June 2020 Hung Up By IP Barriers

Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.

F1
Pfizer has entered the race for market share in the mult-billion-dollar US pegfilgrastim market • Source: Shutterstock

Pfizer’s Nyvepria (pegfilgrastim-apgf) biosimilar is now available in the US, according to a leading investment bank, despite ongoing patent infringement litigation initiated by Neulasta (pegfilgrastim) sponsor Amgen.

Nyvepria was the fourth biosimilar Neulasta pre-filled syringe product approved by the US Food and Drug Administration in June last...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.